Ultragenyx Pharmaceutical Inc.
RARE
$29.78
$0.260.88%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 19.53% | -15.52% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 19.53% | -15.52% | |||
| Cost of Revenue | -3.44% | -72.80% | |||
| Gross Profit | 61.48% | 89.97% | |||
| SG&A Expenses | -1.31% | 6.43% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -2.78% | -1.71% | |||
| Operating Income | 24.52% | -16.90% | |||
| Income Before Tax | 23.88% | -12.27% | |||
| Income Tax Expenses | -27.71% | 6,994.74% | |||
| Earnings from Continuing Operations | 23.91% | -13.27% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 23.91% | -13.27% | |||
| EBIT | 24.52% | -16.90% | |||
| EBITDA | 25.89% | -18.33% | |||
| EPS Basic | 25.59% | -12.55% | |||
| Normalized Basic EPS | 25.49% | -12.75% | |||
| EPS Diluted | 25.59% | -12.55% | |||
| Normalized Diluted EPS | 25.49% | -12.75% | |||
| Average Basic Shares Outstanding | 2.26% | 0.63% | |||
| Average Diluted Shares Outstanding | 2.26% | 0.63% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||